Kymera Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M |
| Cost of revenue | $39.2M | $47.1M | $78.6M | $46.8M | — |
| Research and development | $316.6M | $240.2M | $189.1M | $164.2M | $137.0M |
| Operating expenses | $388.6M | $308.7M | $244.1M | $208.1M | $173.4M |
| Operating income | -$349.4M | -$261.6M | -$165.5M | -$161.3M | -$100.5M |
| Pretax income | -$311.4M | — | — | — | — |
| Income tax expense | $0 | — | — | $0 | $0 |
| Net income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$100.2M |
| Balance Sheet | |||||
| Cash and equivalents | $357.0M | $120.3M | $110.0M | $68.4M | $48.0M |
| Current assets | $871.2M | $510.3M | $405.3M | $419.4M | $451.3M |
| Total assets | $1.7B | $978.0M | $575.8M | $603.1M | $605.9M |
| Current liabilities | $83.2M | $67.8M | $85.7M | $71.3M | $92.5M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M |
| Stockholders' equity | $1.6B | $835.6M | $395.0M | $490.2M | $459.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$232.9M | -$194.5M | -$102.8M | -$153.1M | -$128.9M |
| Depreciation and amortization | $8.3M | $7.4M | $3.6M | $3.0M | $2.4M |
| Stock-based compensation | $59.9M | $55.0M | $43.1M | $35.5M | $25.0M |
| Capital expenditure | $1.4M | $12.8M | $34.5M | $2.8M | $1.6M |
| Free cash flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M | -$130.5M |
| Impairments | $3.9M | $4.9M | $0 | $0 | — |
Shares outstanding 82.3M · Free float 69.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.